Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus

Código QR

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus

Ip Tim Lau,1 Ka Fai Lee,2 Wing Yee So,3 Kathryn Tan,4 Vincent Tok Fai Yeung5 1Department of Medicine, Tseung Kwan O Hospital, 2Department of Medicine and Geriatrics, Kwong Wah Hospital, 3Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, 4Department o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lau IT, Lee KF, So WY, Tan K, Yeung VTF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Diabetes Mellitus Long-acting Insulin Insulin Glargine Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/7bf9792a91224c5ba421aa31716f6fc6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

rDNA insulin glargine U300 – a critical appraisal
por: Wang F, et al.
Publicado: (2016)

On the safety of insulin Glargine
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009)

Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations
por: L. N. Shitov, et al.
Publicado: (2019)

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
por: Thomann R, et al.
Publicado: (2020)

Use of basal insulin and the associated clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus: a retrospective chart review study
por: Davis KL, et al.
Publicado: (2014)

Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
por: Liu D, et al.
Publicado: (2021)

Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
por: Vadim Valer'evich Klimontov, et al.
Publicado: (2014)

Basal insulin therapy in patients with type 2 diabetes mellitus and poor control of glycemia by oral hypoglycemic agents: results of direct comparative study of insulin analogs Lantus and Levemir
por: Alsu Gafurovna Zalevskaya, et al.
Publicado: (2010)

Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience
por: Chan WB, et al.
Publicado: (2017)

Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
por: Nader ND, et al.
Publicado: (2020)

Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2010)

A Difference Between Bedtime and Pre-Breakfast Plasma Glucose Levels Indicates the Need for Prandial Insulin in Basal Insulin-Treated Type 2 Diabetic Patients with Normal Fasting Glucose
por: Kress S, et al.
Publicado: (2021)

Análogos de insulina: en búsqueda del reemplazo fisiológico
por: Eyzaguirre C,Francisca, et al.
Publicado: (2006)

When basal insulin is not enough: successful strategies for insulin intensification in patients with type 2 diabetes mellitus
por: Elena V. Buryukova, et al.
Publicado: (2017)

Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents
por: Tamara Leonidovna Kuraeva
Publicado: (2014)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan TJE, et al.
Publicado: (2021)

Effective and safe control of glycemia with insulin Apidra - the recipe for success of type 2 diabetes prophylaxis
por: Elena Valer'evna Biryukova
Publicado: (2011)

Priority areas in management of diabetes mellitus type 1 & 2 (following 47th EASD Annual Meeting)
por: Ivona Renata Yarek-Martynova, et al.
Publicado: (2011)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014)

Modern approach to basal-bolus therapy with glargine and glulisine insulin analoguesin various age groups
por: Natalya Nikitichna Volevodz, et al.
Publicado: (2013)

Overcoming marked insulin resistance in a patient with type 2 diabetes mellitus by means of insulin pumptherapy
por: Ekaterina Viktorovna Artemova, et al.
Publicado: (2012)

La insulinoterapia intensificada más antineuríticos es superior a antineurítico puro en neuropatía diabética dolorosa
por: Bastías A,M Juliana, et al.
Publicado: (2006)

Insulin signaling proteins in pancreatic islets of insulin-resistant rats induced by glucocorticoid
por: De Paula,Flávia MM, et al.
Publicado: (2011)

The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
por: M. V. Shestakova, et al.
Publicado: (2021)

Modern basal insulins: an ongoing story or the start of a new era?
por: Ivan Ivanovich Dedov
Publicado: (2015)

Achieving Effective and Efficient Basal Insulin Optimal Management by Using Mobile Health Application (APP) for Type 2 Diabetes Patients in China
por: Cai X, et al.
Publicado: (2020)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Schwartz S
Publicado: (2010)

Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications
por: Wondmkun YT
Publicado: (2020)

RELUCTANCE OF PATIENTS WITH DIABETES MELLITUS TO INSULIN THERAPY; PSYCHOLOGICAL INSULIN RESISTANCE
por: Umair Ali, et al.
Publicado: (2021)

Physicochemical stability of human insulin 1 I.U./mL infusion solution in 50 mL polypropylene syringes
por: Mohr André, et al.
Publicado: (2021)

Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2015)

Rapid Desensitization for Insulin Allergy in Type 1 Diabetes Using an Insulin Pump: A Case Report and Literature Review
por: Kristy Tian, MBBS, MRCP, MMed, et al.
Publicado: (2021)

Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
por: Kalirai S, et al.
Publicado: (2020)

Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
por: Elena Valer'evna Biryukova, et al.
Publicado: (2012)

Individual stepwise intensification of insulin analogue therapy in type 2 diabetes mellitus
por: Alexander Sergeevich Ametov, et al.
Publicado: (2012)

Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment
por: Tatiana Ivanovna Romantsova, et al.
Publicado: (2013)

Pengaruh Latihan Fisik terhadap Perbaikan Resistensi Insulin
por: Devitya Angielevi Sukarno
Publicado: (2021)

Effect of different direct-acting antiviral regimens for treatment of nondiabetic hepatitis C virus–infected Egyptian patients on insulin resistance and sensitivity
por: Tarek Yosef, et al.
Publicado: (2021)

Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes
por: Eby EL, et al.
Publicado: (2015)

An Application of Queueing Theory to the Relationship Between Insulin Level and Number of Insulin Receptors
por: Cagin Kandemir-Cavas, et al.
Publicado: (2007)